BixiBat: Safe Relief for Chronic Constipation Patients with Diabetes, Chronic constipation, Elobixibat, General Practitioner, Consultant Physician, General Practice, Constipation Management, Gastroenterology, Gastroenterologist, Consultant Physician, SBM: Spontaneous Bowel Movement, CSBM: Complete Spontaneous Bowel Movement
This article is brought to you by Bixibat
This Article is brought to you by BixiBat
Elobixibat Is Safe and Effective to Use in Patients With Diabetes and Chronic Constipation
 |
A prospective, single-center, single-arm study to investigate the efficacy and safety of elobixibat in patients with diabetes and chronic constipation |
 |
33 patients (≥20 years) with diabetes and chronic functional constipation (Rome IV criteria) |
 |
Elobixibat 10 mg/day (adjustable, max. 15 mg/day) |
|
No serious AEs occurred during the study period. |
 |
One patient possibly experienced diarrhea (3%). |
 |
ConclusionEfficacy and safety of elobixibat was confirmed in patients with diabetes and chronic constipation. |
*p<0.05; **p<0.01; #As assessed by JPAC-QOL score.
AE: Adverse event; BSFS: Bristol Stool Form Scale; FPG: Fasting plasma glucose; HbA1c: Glycated hemoglobin; JPAC-QOL: Japanese version of the patient assessment of constipation quality of life; QoL: Quality of life; SBM: Spontaneous bowel movement. Reference: Hishida Y, Nagai Y, Tsukiyama H, et al. Effects of Elobixibat in patients with diabetes and concomitant chronic constipation: An 8-week, prospective, single-center, single-arm study. Adv Ther. 2022;39(9):4205–4217.
For the use of a Registered Medical Practitioner, Hospital or a Laboratory only. GGI-CO-A1-AQS-300041570-ELC-L24-0760
